Market Playbook

November 18, 2024

DENVER, Colo., Nov 18, 2024 (247marketnews.com)- Siyata Mobile (NASDAQ: SYTA), SINTX Technologies (NASDAQ: SINT), HCW Biologics (NASDAQ: HCWB), and NewGenIvf Group (NASDAQ: NIVF)

Siyata Mobile (NASDAQ: SYTA) reported more than tripling third quarter 2024 revenue and set a new Company quarterly revenue record of $5.9 million, a 218%, or over $4 million, year-over-year increase and a 210%, or $4.0 million, quarter-over-quarter increase.

Siyata traded over 5.9 million shares, which is greater than Siyata’s reported outstanding shares, indicating that the shorts are very busy in Siyata’s market and that there may be some trades that haven’t yet settled, so look for a potential squeeze rebound.

Marc Seelenfreund, Siyata’s CEO, stated, “We are also extremely excited with our sales outlook going forward as we are now seeing tangible, rapid adoption of our unique PTT product portfolio across our various sales channels.  We believe that we have a very exciting 5G product portfolio planned to launch in 2025 which will position us as the leading PTT handset provider on a global level.  We announced recently that T-Mobile is the first wireless carrier that will be launching part of the portfolio and will be releasing details of the innovative devices over the coming months.  We are optimistic that more wireless carriers will follow suit.”

Siyata’s strategy was to place Siyata’s PTT devices into the top carriers, including AT&T (NYSE: T), Verizon (NYSE: VZ), and T-Mobile (NASDAQ: TMUS), so that the Company can benefit from potential cobranding deals, and the results are reflected in the third quarter results.

SINTX Technologies (NASDAQ: SINT) reported that its board of directors approved a buy back of up to $500,000 of the Company’s outstanding common stock, or about 20% of total outstanding shares, over the next several quarters.

Eric Olson, CEO of SINTX Technologies, commented, “We believe that the current market undervalues SINTX’s potential. This repurchase program underscores our confidence in the company’s strategic initiatives and our commitment to delivering value to our shareholders. By leveraging our strong balance sheet, we are taking a proactive approach to capital allocation, similar to other companies in our industry that have successfully implemented share repurchase programs.”

HCW Biologics (NASDAQ: HCWB) stated that it entered into license, research and co-development agreement with China-based WY Biotech, which specializes in early-stage development of recombinant protein drugs and gene/cell therapies.

WY Biotech will pay a $7 million upfront payment to HCWB, and HCWB is eligible to receive additional significant development milestone payments and double-digit royalties on future product sales, while HCWB will share a substantial portion of the proceeds from potential transaction(s) involving the molecule. HCWB also has an option to recapture the development and commercialization rights of this molecule for the United States, Canada, Central America, and South America (Opt-in Territory) after the Phase 1 clinical trial concludes.

Dr. Hing C. Wong, HCWB’s CEO and Founder, commented, “HCW Biologics’ strategic focus has been to establish commercialization partnerships for its novel protein and antibody therapies with innovative leaders in the immunotherapy field.

“To this end, we have leveraged our in-depth knowledge of T cell and natural killer (NK) cell immunology and our brand-new proprietary drug discovery platform technologies to develop a portfolio of three classes of potent immunotherapeutics: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors and Multi-Specific Targeting Fusions; and Class III: Enhanced Immune Cell Engagers. We have developed molecules in each of these classes for treatments of hematologic and solid tumors, virally infected cells, and cellular senescence diseases associated with ageing. The product candidate subject to the license with WY Biotech combines several different immune functional domains on our new protein scaffold platform as part of our Class I portfolio. Our preclinical studies demonstrated that this multi-functional product candidate is highly effective at inducing anti-tumor CD8+ T cell and NK cell responses without triggering unwanted side effects in relevant solid tumor animal models. It appears to be one of the most potent immunostimulatory agents we have developed in over 30 years of biotech research and should combine well with other therapies, including immune checkpoint inhibitors, immune cell engagers, therapeutic antibodies, and CAR-T therapies. We are very excited that WY Biotech recognizes the potential and value of this preclinical Class I molecule for human therapy. We are very much looking forward to collaborating with them on the clinical and commercial development of this novel approach.”

NewGenIvf Group (NASDAQ: NIVF) reported entering into a binding term sheet for a $100 million equity line of credit, expandable to $500 million, with White Lion Capital, an institutional investor that’s focused on high-growth, early-stage public companies.

The term sheet provides NewGen the option, but not the obligation, to sell to White Lion up to $100 million in shares of common stock over an initial 3-year period, which is expandable up to $500 million after certain milestones have been met.

Siu Wing Fung Alfred, NewGen’s Founder, Chairman, and CEO, stated, “This major agreement marks another significant milestone in NewGen’s growth trajectory. With an initial commitment of $100 million, expandable to $500 million, this facility provides us with substantial financial flexibility and demonstrates the confidence our new institutional partner has in our business model and growth prospects.

“From a strategic perspective, this financing facility aligns perfectly with our expansion plans across Asia. Importantly, the agreement’s built-in scalability, particularly the provision to increase to $300 million upon substantial M&A or merger activity, gives us the firepower to act decisively when further opportunities arise in our rapidly evolving market. The flexibility to draw capital at our discretion enables us to maintain our strong balance sheet while pursuing potential strategic acquisitions. Moreover, the 36-month term, extendable to 65 months, provides us with a long-term capital partner to support our growth initiatives. We welcome White Lion to our roster of shareholders and look forward to strategically deploying this capital to drive sustainable growth and shareholder value.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information. 24/7MN Will receive $2500 from a third party for covering Siyata this week and providing other services.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (SYTA, SINT, HCWB, NIVF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.